Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy

Kasey Leger, Tamra Slone, Matthew Lemler, David Leonard, Cindy Cochran, W. Paul Bowman, Lisa Bashore, Naomi Winick

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100mg/m2. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline. Procedure: Conventional 2-dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100mg/m2,an average of 9.8 years from diagnosis. LV structural measurements were converted into Z-scores. The Z-score distributions were compared to those of the normal population. Diastolic and systolic function were quantified. Results: The cohort demonstrated a decreased posterior wall thickness (mean Z-score -1.01) and mildly decreased LV end diastolic (mean Z-score -0.85) and systolic (mean Z-score -0.84) dimensions compared to the normal population (P<0.001). Further, 28% of patients (n=25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z-score ≤-2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF≤28%. Conclusions: A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalPediatric Blood and Cancer
Volume62
Issue number1
DOIs
StatePublished - 1 Jan 2015

Fingerprint

Anthracyclines
Survivors
Neoplasms
Therapeutics
Left Ventricular Function
Population
Heart Diseases
Cardiotoxicity
Radiation

Keywords

  • Cardiotoxicity
  • Late effects of cancer treatment
  • Pediatric oncology

Cite this

Leger, Kasey ; Slone, Tamra ; Lemler, Matthew ; Leonard, David ; Cochran, Cindy ; Bowman, W. Paul ; Bashore, Lisa ; Winick, Naomi. / Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 1. pp. 123-127.
@article{08f3ebd06a0e43dbb4dd20b58b618a08,
title = "Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy",
abstract = "Background: Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100mg/m2. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline. Procedure: Conventional 2-dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100mg/m2,an average of 9.8 years from diagnosis. LV structural measurements were converted into Z-scores. The Z-score distributions were compared to those of the normal population. Diastolic and systolic function were quantified. Results: The cohort demonstrated a decreased posterior wall thickness (mean Z-score -1.01) and mildly decreased LV end diastolic (mean Z-score -0.85) and systolic (mean Z-score -0.84) dimensions compared to the normal population (P<0.001). Further, 28{\%} of patients (n=25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z-score ≤-2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF≤28{\%}. Conclusions: A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline.",
keywords = "Cardiotoxicity, Late effects of cancer treatment, Pediatric oncology",
author = "Kasey Leger and Tamra Slone and Matthew Lemler and David Leonard and Cindy Cochran and Bowman, {W. Paul} and Lisa Bashore and Naomi Winick",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/pbc.25206",
language = "English",
volume = "62",
pages = "123--127",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Leger, K, Slone, T, Lemler, M, Leonard, D, Cochran, C, Bowman, WP, Bashore, L & Winick, N 2015, 'Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy', Pediatric Blood and Cancer, vol. 62, no. 1, pp. 123-127. https://doi.org/10.1002/pbc.25206

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. / Leger, Kasey; Slone, Tamra; Lemler, Matthew; Leonard, David; Cochran, Cindy; Bowman, W. Paul; Bashore, Lisa; Winick, Naomi.

In: Pediatric Blood and Cancer, Vol. 62, No. 1, 01.01.2015, p. 123-127.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy

AU - Leger, Kasey

AU - Slone, Tamra

AU - Lemler, Matthew

AU - Leonard, David

AU - Cochran, Cindy

AU - Bowman, W. Paul

AU - Bashore, Lisa

AU - Winick, Naomi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100mg/m2. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline. Procedure: Conventional 2-dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100mg/m2,an average of 9.8 years from diagnosis. LV structural measurements were converted into Z-scores. The Z-score distributions were compared to those of the normal population. Diastolic and systolic function were quantified. Results: The cohort demonstrated a decreased posterior wall thickness (mean Z-score -1.01) and mildly decreased LV end diastolic (mean Z-score -0.85) and systolic (mean Z-score -0.84) dimensions compared to the normal population (P<0.001). Further, 28% of patients (n=25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z-score ≤-2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF≤28%. Conclusions: A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline.

AB - Background: Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100mg/m2. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline. Procedure: Conventional 2-dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100mg/m2,an average of 9.8 years from diagnosis. LV structural measurements were converted into Z-scores. The Z-score distributions were compared to those of the normal population. Diastolic and systolic function were quantified. Results: The cohort demonstrated a decreased posterior wall thickness (mean Z-score -1.01) and mildly decreased LV end diastolic (mean Z-score -0.85) and systolic (mean Z-score -0.84) dimensions compared to the normal population (P<0.001). Further, 28% of patients (n=25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z-score ≤-2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF≤28%. Conclusions: A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline.

KW - Cardiotoxicity

KW - Late effects of cancer treatment

KW - Pediatric oncology

UR - http://www.scopus.com/inward/record.url?scp=84922827479&partnerID=8YFLogxK

U2 - 10.1002/pbc.25206

DO - 10.1002/pbc.25206

M3 - Article

C2 - 25176022

AN - SCOPUS:84922827479

VL - 62

SP - 123

EP - 127

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -